KU14R

Key Product Details

Product Description

KU14R is a antagonist of the atypical imidazoline binding site (putative I₃ receptor) of pancreatic β-cells. Selectively blocks efaroxan-induced insulin secretion in vitro and in vivo.

Product Specifications for KU14R

The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.

Solubility

Preparing Stock Solutions for KU14R

The following data is based on the product molecular weight 214.27.

Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which all affect the solvent volumes required to prepare stock solutions.

Select a batch to recalculate based on the batch molecular weight:

1 Recalculate

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	4.67 mL	23.34 mL	46.67 mL
5 mM	0.93 mL	4.67 mL	9.33 mL
10 mM	0.47 mL	2.33 mL	4.67 mL
50 mM	0.09 mL	0.47 mL	0.93 mL

Calculators

Background References

References are publications that support the biological activity of the product. See our Citations tab to view 23 publications citing the usage of this product.

• Chan Clotrimazole and efaroxan stimulate Ins secretion by different mechanisms in rat pancreatic islets. Naunyn Schmiedebergs Arch.Pharmacol. 1997 PMID: 9453462
• Mayer and Taberner Effects of the imidazoline ligands efaroxan and KU14R on blood glucose in the mouse. Eur.J.Pharmacol. 2002 PMID: 12409010
• Chan The putative endogenous imidazoline receptor ligand, clonidine-displacing substance, is a potent Ins secretagogue in rat and human islets of Langerhans. Br.J.Pharmacol. 1997 PMID: 9138700

Product Documents for KU14R